- Bradikinin B2 receptor based drugs for angioedema and severe burn, drugs for ophthalmic disease indications
- Investment Period: 3 years
- 2007 IPO on NASDAQ,
- 2008 acquisition by GlaxoSmithKline (GSK) for approximately $720 million (€467 M) through a cash tender offer of $22.50 (€14.59) per share
TVM Capital Life Science provided significant support and guidance to the company from its inception. Specifically, the US-based Partner provided instrumental operations assistance in the structuring and management of company labs, the development of assays, and the development of a strategy to use a contract research organization for medicinal chemistry activities.